Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560461 | 1.00 | TAAR1 (0.47) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL29560858 | 1.00 | TAAR1 (0.47) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL4292448 | 1.00 | TAAR1 (0.47) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL938227 | 1.00 | TAAR1 (0.47) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL4753990 | 0.82 | HTR2A (0.41) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL1023049 | 0.82 | HTR2A (0.50) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL37732 | 0.82 | TSHR (0.57) | TSHRHTR2A | |
| SCHEMBL13140491 | 0.79 | HTR2C (0.36) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL7055337 | 0.79 | ALDH1A1 (0.42) | TAAR1TSHRHTR2AHTR2CHTR2B | |
| SCHEMBL7049820 | 0.77 | TP53 (0.42) | TSHRHTR2AHTR2CHTR2BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | METROCHEM API PVT LTD | 2025-01-02 | — | — | US | disclosed |
| CN-114317620-B | Biological preparation method of (R) -2- (2-chlorophenyl) oxirane | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| CN-114317620-B | Biological preparation method of (R) -2- (2-chlorophenyl) oxirane | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023152711-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE AND INTERMEDIATES THEREOF | METROCHEM API PVT LTD (IN) | 2023-08-17 | — | — | WO | disclosed |
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| WO-2010039911-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039911-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-20080206826-A1 | Method for Producing Single Enantiomer Epoxides by the Adh Reduction of a-Leaving Group-Substituted Ketones and Cyclization | ARCHIMICA GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1879873-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-7153971-B2 | Contacting a carbohydrate with an amine to produce amino tetrahydroxy carbohydrate, protecting two hydroxy groups of tetrahydroxy carbohydrate, forming hydroxy heterocyclic-spiro moiety by reacting with activated carbonate, oxidizing OH | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| WO-2006112685-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2006-10-26 | — | — | WO | disclosed |
| WO-2005037811-A1 | A METHOD FOR THE PRODUCTION OF CHIRAL SUBSTITUTED EPOXIDES | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) | 2005-04-28 | — | — | WO | disclosed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-02-26 | — | — | US | disclosed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | TAAR1 1080/4885TSHR 2776/4885HTR2A 1248/4885 |
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | TALDO1, AURKB, PGD | TAAR1 2163/4885TSHR 4785/4885HTR2A 4596/4885 |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | OXER1, OXA1L, AOX1 | TAAR1 2743/4885TSHR 4087/4885HTR2A 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.